Healthy, Migraine
Conditions
Keywords
VIP, PACAP, CGRP, Prostanoids
Brief summary
The study aim at examining whether Sumatriptan changes the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.
Detailed description
The study is meant to give a better understanding of the basic mechanisms behind migraine, and a better understanding of the effects of sumatriptan on the trigemino vascular system. The endpoints are changes in the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.
Interventions
DRUGsumatriptan
Sponsors
Glostrup University Hospital, Copenhagen
Bispebjerg Hospital
Danish Headache Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy volunteers * 18-50 years, * 50-100 kg. * Fertile women must use birth control.
Exclusion criteria
* All primary types of headache * Daily intake of medicine except birth control * Pregnancy * Hypertension * Hypotension * other chronic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood concentration of vasoactive intestinal polypeptide (VIP), | — |
| calcitonin gene-related protein (CGRP), pituitary adenylate cyclase | — |
| activating peptide (PACAP,) and the prostanoids | — |
| 6-keto-PGF1α, PGE2, PGD2 and PGF2α, sampled from different | — |
| venous catheters. | — |
Countries
Denmark
Outcome results
None listed